Abstract. Oligomeric and fibrillar ␤-amyloid (A␤) may be toxic in Alzheimer disease (AD), especially after post-translation modification cumulative over time. Racemization of Ser and Asp residues of A␤ in senile plaques (SPs) occurs as an agedependent process in AD. We previously reported that A␤1-40 
INTRODUCTION
␤-Amyloid (A␤) is the principal component of senile plaques (SPs). Neurotoxicity of fibrillar A␤ in vitro has been reported by many investigators (1-3) as a major contributor to AD pathogenesis (4) (5) (6) (7) . We previously demonstrated that fibrillar A␤ produces dramatic neurodegeneration in vivo by enhancing the susceptibility of neurons to excitatory amino acids (8, 9) . However, the temporal and topographical dichotomy between the appearance of SPs and the neurofibrillary degeneration in AD remains unresolved. It is unclear if insoluble, fibrillar A␤ per se is directly responsible for the neurodegeneration (10, 11) . Initially, A␤ deposits appear as diffuse plaques 20 to 30 years prior to the neurofibrillary degeneration in Alzheimer disease (AD) (12, 13) . Second, large accumulations of A␤ induce little or no neurodegeneration in brains of transgenic mice (5, 6) . Third, the hippocampal CA1 region, and the subiculum, both vulnerable areas early in AD, are more typically spared of A␤ deposition, especially in the early stage (14) . Finally, soluble oligomeric forms of A␤ species have been implicated with toxicity linked to AD (15, 16) . These observations suggest that a multistep, age-dependent solubilization processing of A␤ may be necessary to induce degeneration in AD patients.
Racemization of Ser and Asp residues especially in insoluble and nonmetabolized proteins is a typical agedependent process, and is known to be responsible for some age-related diseases in humans (17, 18) . A␤1-40 has 2 Ser (#8, 26) and 3 Asp (#1, 7, 23) residues. Considerable amounts (5%-10%) of D-Ser and D-Asp are present in insoluble A␤ in SPs from AD brains (19) (20) (21) .
To explore the possible roles of racemization of A␤ in the pathogenesis of AD, we focused on A␤ racemized at the Ser (22) . These observations suggest a series of events initiated by age-dependent racemization of A␤1-40 in SPs followed by increasing solubility, then release from plaques, and conversion by brain proteases to a toxic form, either [ 26 in SPs are detected by antiserum 20.1 in AD brains. On cryosections (10 m) of hippocampus and amygdala from AD patients (A, C-F) and a control subject (B), immunohistochemistry was performed with antiserum 20.1 (A-C, E, F). Antigen retrieval with formic acid was performed prior to staining (A, B, E, F), and (D) is stained with thioflavin S. Antiserum 20.1 stained many circumscribed foci suggestive of SPs, seen in red, in the amygdala (A) of an AD brain (AD-7) and subiculum (C) of another AD brain (AD-4) but had no immunoreactivity in the amygdala (B) of the control brain (Control-4). Preimmune serum had no immunoreactivity in AD brains (data not shown). At higher magnification, the 20.1-positive SP (C) in the subiculum of AD (AD-4) was also stained by thioflavin S (D) in a serial section. Racemized and truncated A␤ was further confirmed after immuno-absorption (E, F) whereby immunostaining of the amygdala from AD brain (AD-7) was performed following preincubation of 20 AD-affected brains and in age-matched control brains was examined. 
MATERIALS AND METHODS Subjects
The amounts of neuritic plaques and vascular amyloids in the entorhinal cortex and those of NFTs in hippocampal CA1 were semiquantitatively scored as follows: Ϫ ϭ none, ϩ ϭ sparse, ϩϩ ϭ moderate, ϩϩϩ ϭ frequent. In addition, the Braak stage of each case was determined by grading scheme shown in reference 14 and 25.
Abbreviations: PMD, postmortem delay; F, female; M, male; ALS, amyotrophic lateral sclerosis. * This case had sparse neuritic plaques but numerous diffuse plaques.
regions at autopsy, snap-frozen in liquid nitrogen-chilled isopentane (Sigma-Aldrich, St. Louis, MO), and stored at Ϫ80ЊC until use. These sites were selected as they have the earliest pathology in AD, and thus most likely to have racemized A␤. Included were 11 clinically and neuropathologically confirmed AD patients and 7 control subjects, including 2 amyotrophic lateral sclerosis (ALS) patients without either a clinical history of dementia or AD-related neuropathological changes ( Table 1) . The average ages of AD patients and control subjects were 75.5 and 73.6 years, respectively. Mean postmortem intervals were 4.5 hours (h) (range 3 h-8 h) for AD and 6.5 h (range 4 h-12 h) for controls. The number of neuritic plaques and vascular amyloid deposits in the entorhinal cortex and neurofibrillary tangles (NFTs) in the hippocampal CA1 region was each semiquantitatively scored using a modified CERAD protocol (24) and Braak staging was employed for the grading of histopathology (14, 25) .
Peptides and Antibodies
Human A␤ peptides containing D-amino acids were synthesized as previously described (1) with a cysteine at the carboxyl terminus, respectively. Synthesis of peptide immunogens, immunization of rabbits, and collection of antisera were performed at Asahi Techno Glass Corporation (Tokyo, Japan). Aliquots of antisera as well as preimmune sera were frozen at Ϫ80ЊC. We used whole antisera (20.1 and 22.7) in the experiments, but each purified rabbit IgG obtained by using a protein-A conjugated agarose column (Bio-Rad Laboratories, Hercules, CA) showed the same staining patterns (data not shown). Anti-A␤ antibodies, 6E10 and 4G8, recognizing amino acids 1-17 and 17-24 of A␤, respectively, were purchased from Senetek (Maryland Heights, MO). Polyclonal rabbit anti-A␤40 and A␤42 C-terminal antibodies were obtained from Biosource International, Inc. (Camarillo, CA). AT-8 (Innogenetics, Ghent, Belgium) was used to visualize hyperphosphorylated tau. Anti-amyloid precursor protein (APP) antibody, 22C11, and anti-tau antibody, tau-1, were purchased from Research Diagnostics (Flanders, NJ) and Roche Diagnostics (Mannheim, Germany), respectively. 
Enzyme-Linked Immunosorbent Assay (ELISA) Analysis

Immunohistochemistry
Cryostat sections (10 m) were placed onto slides coated with polylysine (Matsunami Glass, Osaka, Japan). Unless otherwise mentioned, antigen retrieval treatments of sections were performed. Sections were fixed with 10% formalin (Wako Pure Chemical Industries, Osaka, Japan) for 30 min, treated with 98% to 99% formic acid (Sigma-Aldrich) for 10 min at room temperature, incubated in 3% hydrogen peroxide (Sigma-Aldrich) in methanol (Wako Pure Chemical Industries) for 30 min, then in 10% normal goat serum (Chemicon International, Temecula, CA) in PBS for 2 h at room temperature to block endogenous peroxidase activity and nonspecific staining, respectively. Thereafter, sections were reacted with primary antibodies in PBS at 4ЊC overnight. Anti-[D- A␤ from L-form A␤ since deposits of L-form A␤ (A␤25-35), when injected into the hippocampus of rats, were negative for the staining with 20.1 or 22.7 even after the same antigen retrieval treatment (Kubo et al, unpublished results). We also observed enhanced staining with 20.1 and 22.7 by microwave-boiling the sections at 90ЊC for 10 min, another antigen retrieval treatment. For specific inhibition of immunostaining by 20.1 or 22.7, each antiserum was preincubated with competitive peptides for 2 h at room temperature before application to the sections. All other antibodies (6E10, 4G8, anti-A␤40 and A␤42 C-terminal antibodies, and AT-8) were used at a dilution of 1:100. The appropriate secondary antibody (Transduction Laboratories, Lexington, KY) conjugated with HRP (anti-rabbit IgG for 20.1, 22.7 or anti-A␤40 and A␤42 C-terminal antibodies, and anti-mouse IgG for 6E10, 4G8, or AT-8) was applied at a dilution of 1:100 to sections at room temperature for 1 h. A red chromogen, 3-amino-9-ethylcarbazole (AEC, Zymed Laboratories, South San Francisco, CA) was used as substrate. Sections were counterstained with hematoxylin.
For double labeling, staining with AT-8 was sequentially performed after staining with 22.7 and AEC was completed. After incubation with AT-8 at room temperature for 1 h, a biotinylated anti-mouse IgG antibody (Vector Laboratories, Burlingame, CA) was applied to the sections at a 200-fold dilution, incubated for an additional 1 h, and visualized with the avidin-biotin method using an alkaline phosphatase-based kit (Vectastain ABC-AP and Vector Blue, Vector Laboratories). For double labeling with 22.7 and anti-A␤40 C-terminal antibody, sections stained by anti-A␤40 C-terminal antibody and AEC were incubated with protein-A-purified 22.7, previously biotinylated with the Sulfo-NHS-Biotinylation kit (Pierce, Rockford, IL) according to the manufacturer's instructions. Development of 22.7-immunoreactivity was performed by the avidin-biotin method with alkaline phosphatase. Counterstaining was omitted in the double-labeled sections.
For immunofluorescent double labeling, sections stained by 20.1 and Texas Red-X-conjugated anti-rabbit IgG (1:100, Molecular Probes, Eugene, OR) were subsequently labeled with 4G8 or 6E10 and Oregon Green 488-conjugated anti-mouse IgG (1:100, Molecular Probes). For thioflavin S-staining, sections without formic acid treatment were incubated with 1% thioflavin S (Sigma-Aldrich) at room temperature for 7 min. After washing sequentially in 95% and 80% ethanol (Wako Pure Chemical Industries), sections were hydrated and coverslipped for observation. We previously hypothesized that A␤ racemized at Ser 26 plays an important role in the pathogenesis of AD (22, 23) . In the present study, we developed 2 polyclonal antisera, (20 (Fig. 1A, B To further examine the specificity of these 2 antisera, we performed the competitive experiments in ELISA as follows: Diluted antiserum (20.1 or 22.7) was preincubated with competitive peptides for 2 h before application to plates coated with [D-Ser 26 ]A␤25-35, and then immunoreactivity determined as described in Materials and Methods. The data shown in Figure 1C clearly Fig. 2A, C) . Corresponding preimmune serum showed no immunoreactivity (data not shown). Plaque cores immunoreactive with 20.1 were detected in the 9 AD brains, all with abundant neuritic plaques in the entorhinal cortex (Table 1) . No significant immunoreactivity was observed in all 7 agematched controls, which were virtually free of neuritic plaques ( Fig. 2B; Table 1 ). In the CNS of 1 AD patient (AD-8) with many diffuse plaques but a few neuritic plaques, no immunoreactivity with 20.1 was detected either in the entorhinal cortex, amygdala, or hippocampus.
Western Blotting
Immunostaining of 20. with A␤25-35 (Fig. 2E, F (Fig. 2C, D (Fig. 3A) . In contrast, 6E10 labeled some of the 20.1-positive deposits (Fig. 3B) . It should be noted that 20.1 immunoreactivity was concentrated in the plaque cores and surrounded by 4G8 or 6E10-positive A␤ halos (Fig. 3A, B, E ). In contrast, 20.1-staining was not observed in 4G8-positive diffuse plaques (Fig. 3C-E, arrows) . These results indicate racemized forms of A␤ aggregated within the plaque cores.
We analyzed brains obtained from 2 AD patients (AD-3 and AD-4) with typical amyloid angiopathy ( Table 1) . The vascular media were also intensely stained by 20.1 and in serial sections, the 20.1-positive vascular deposits also reacted with 6E10 and thioflavin S (Fig. 4A-D) , suggesting a ␤-pleated structure is included in at least some of the A␤ fragments.
Extracellular ''ghost tangles'' contain 20.1-immunoreactive racemized A␤. Antibody 20.1-positive NFTs were present in the hippocampal CA1 and CA2 regions of 3 AD (AD-4, AD-10, and AD-11) patients (Fig. 4E,  F ; Table 2 ). Although dependent on the section orientation, these 20.1-positive tangles had no associated nucleus and a less compact fibrillary structure suggestive of extracellular or ''ghost'' tangles (26, 27) . In contrast, in tissues of all 10 AD patients (see below), the 20.1 antiserum did not stain the 22.7-positive intracellular NFTs within pyramidal neurons where nuclei were clearly apparent. With regards to both the vascular amyloid and extracellular NFTs, the 20. Figure 5 shows typical immunostaining by 22.7 of neurons with NFT in the AD-affected hippocampal CA1 region and a normal control. Although plaques remained unstained, many, but not all pyramidal neurons in the hippocampal CA1 region were reactive with 22.7. Thioflavin-S-positive pyramidal neurons confirmed localization of the NFTs (not shown). A corresponding preimmune serum exhibited no staining in AD brains (data not shown). In AD-affected brains, similar 22.7-positive neuronal staining was also frequently observed in neurons of the amygdala, entorhinal cortex, and subiculum (data not shown) but not in hippocampal CA3 or dentate granule neurons ( Table 2) .
Immunoreactivity of 22.7 was detected in the neuronal cytoplasm but not in the nuclei (Fig. 5A, B, D) . There was a gradation of immunoreactivity among neurons; 10% to 20% of positive neurons were strongly stained and the remainder moderately or weakly reactive. Glial cells in those areas were not labeled with 22.7. We observed 22.7-positive neurons in all 10 AD brains tested (AD-1, AD-3-AD-11; AD-2 was not tested), but no significant staining in the 7 control brains (Fig. 5C and data not shown). Most of the 22.7-positive neurons were of comparable size to intact, unstained pyramidal neurons, although there were a few larger cells with a ghost tanglelike appearance (Fig. 5A, B, D and data not shown) . Among the 22.7-positive neurons, nuclei were visualized by either hematoxylin (Fig. 5A, B) or by double labeling with 22.7 and Hoechst 33258, a fluorescent nuclear stain (Fig. 5D, E) . These results suggest that such intact neurons already contained 22.7-positive and truncated [DSer 26 ]A␤-peptides and neurofibrillary changes. As shown in Figure 5F and G, most 22.7 immunoreactivity was inhibited by preincubation of 22. (Fig. 1D) Immunostaining of the CA1 region in AD-affected brain was performed using both 22.7 and AT-8, a monoclonal antibody recognizing hyperphosphorylated tau in degenerating neurons containing NFTs. Although AT-8 stained numerous NFTs, neuropil threads, and neuritic plaques (Fig. 6B) , 22.7 reacted with some of the AT-8-positive neuronal somata, but not AT-8-positive neuropil threads or neuritic plaques (Fig. 6C, E) . Colocalization of 22.7-immunoreactivity and abnormal tau in NFTs was confirmed by sequential labeling with 22.7 and AT-8: Some neurons containing AT-8-positive NFTs were also stained with 22.7 (Fig. 6E) . By semiquantitative analysis, To check possible cross-reactivity of 22.7 to intracellular AD-related proteins such as APP, tau, and hyperphosphorylated tau, we performed Western blotting of AD (AD-9 and AD-11) and control (C-5 and C-6) hippocampal homogenates. 22.7 did not label any bands in all AD and control homogenates, whereas antibodies 22C11, tau-1 and AT-8 clearly detected APP, tau, and hyperphosphorylated tau, respectively, in AD homogenates (data not shown 26 ]A␤ peptides in cores of senile plaques, but not in numerous diffuse plaques and relatively sparse neuritic plaques in the AD patients, supports the idea that A␤ proteins may be further modified during age-dependent plaque maturation from diffuse to neuritic plaques in AD brains (30, 31) . These observations are consistent with a previous report that racemization of aspartate residues in A␤ was detected in neuritic plaques in AD brains (32, 33) .
A␤ proteins in SPs are reported to consist of various lengths of A␤ fragments (20) , which is also the case of the racemized A␤ species in AD. In the present study, all of the 20.1-positive plaques colocalized with those stained with 4G8 whose epitope is within A␤17-24, while some were not stained with 6E10 whose epitope is within A␤1-17. The 20.1-positive and 6E10-negative plaques are more likely to be mature plaques containing mainly N-terminally truncated A␤ produced during aging by the extensive action of brain proteases such as aminopeptidases. This assumption is supported by the observation that senile plaques are degraded in an age-dependent manner (34, 35) . brain (AD-8) , and were undetectable in neurons with a significant level of NFT in a control subject (C-2) ( (Fig. 5F ). This assumption is also supported by the fact that the 22.7-positive neurons remained unstained with 20.1, which binds to A␤ species with D-Ser 26 at their N-terminus. We also confirmed the colocalization of 22.7-positive antigens and C-terminal fragments of A␤40 within neurons by sequential immunostaining of C-terminal Val 40 -specific, anti-A␤40 (Fig. 6D ). However, it should be noted that some of the strong, 22. Several investigators previously reported A␤-immunoreactivity within neurons and with extracellular NFTs in AD brains (36) (37) (38) (39) . It has been suggested that the A␤-immunoreactivity of extracellular NFTs might result from secondary deposition of A␤ onto extracellular NFTs after neuronal death (27) . However, the 22.7-positive neurons exhibit similar morphology as unaffected neurons, suggesting that accumulation of toxic [D-Ser 26 ]A␤25-40 may begin early in the course of AD changes, when the neurons may still be intact and functional (Fig. 5A, B,  D) . This is consistent with recent observation that intraneuronal accumulation of A␤ x-42 was detected in the early stage of AD pathology (40) . Of note, however, is that 22.7-positive neurons already contain AT-8-positive hyperphosphorylated tau (Fig. 6E) , suggesting an early sign of AD pathology in those neurons. 
